MPPP
| Structural formula | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||||
| General | |||||||||||||
| Surname | MPPP | ||||||||||||
| other names |
|
||||||||||||
| Molecular formula | C 15 H 21 NO 2 | ||||||||||||
| External identifiers / databases | |||||||||||||
|
|||||||||||||
| Drug information | |||||||||||||
| Drug class | |||||||||||||
| properties | |||||||||||||
| Molar mass | 247.33 g mol −1 | ||||||||||||
| safety instructions | |||||||||||||
|
|||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | |||||||||||||
MPPP ( 1-methyl-4-phenyl-4-propion-oxy-piperidine ) is an analgesic opioid , which is also known as synthetic heroin as a designer drug . Structurally it is the reverse ester of pethidine .
The improper manufacture of MPPP produces the nerve toxin MPTP , which causes irreversible Parkinson's- like damage. The correct synthesis of MPPP takes place slowly and with little heat. If a large amount of heat is applied, a large amount of MPTP is produced during the synthesis through the elimination reaction .
MPPP is listed as a non-marketable substance in the BtMG .
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ Langston, JW et al. (1983): Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. In: Science. 219 (4587): 979-980, PMID 6823561 .